Meeting
2020 ASCO Virtual Scientific Program
Hcrn GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC).
Authors
Arjun Vasant Balar
Perlmutter Cancer Center at NYU Langone Health, New York, NY
Arjun Vasant Balar , Samuel Aaron Funt , Shilpa Gupta , Arkadiusz Z. Dudek , Alejandro Recio Boiles , Daniel A. Vaena , Deepak Kilari , Jonathan E. Rosenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT03272217
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS5098)
DOI
10.1200/JCO.2020.38.15_suppl.TPS5098
Abstract #
TPS5098
Poster Bd #
167
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).
First Author: Gabriela Liliana Bravo Montenegro
Poster
2023 ASCO Annual Meeting
A phase II multi-cohort single-arm study of tiragolumab with atezolizumab plus bevacizumab in previously treated advanced non-squamous non–small-cell lung cancer.
First Author: Joshua E. Reuss
Poster
2021 ASCO Annual Meeting
Phase II trial of atezolizumab (A) + carboplatin (C) + pemetrexed (P) + bevacizumab (B) in pts with stage IV non-squamous non-small cell lung cancer (NSq-NSCLC): Big Ten Cancer Research Consortium Study LUN 17-139.
First Author: Fatemeh Ardeshir-Larijani
Poster
2021 Gastrointestinal Cancers Symposium
A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).
First Author: Aiwu Ruth He